Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsThe advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORE
CAR-T combination therapy effectively addresses key challenges in solid tumors, such as the immunosuppressive tumor microenvironment and antigen heterogeneity, by integrating multiple treatment modalities, thereby significantly enhancing anti-tumor efficacy and treatment durability. Creative Biolabs' Solid Tumor Targeting CAR-T Combination Development Services leveraging advanced CAR design platform, multi-modal combination strategy optimization, and robust preclinical translational capabilities to offer end-to-end solutions, from target selection to combination regimen validation and efficacy assessment.
The combination of CAR-T cell therapy with various treatment modalities, such as chemotherapy, radiotherapy, cancer vaccines, and immune checkpoint inhibitors, has emerged as a significant research direction in the field of cancer immunotherapy. This integrated approach acts synergistically to enhance anti-tumor immune responses, modulate the immunosuppressive tumor microenvironment, and overcome key limitations of CAR-T cells in treating solid tumors. In addressing complex challenges such as tumor heterogeneity, antigen escape, and immunosuppressive mechanisms, the adoption of combination strategies is crucial for improving therapeutic outcomes, extending patient survival, and advancing the clinical translation of CAR-T cell technology.
Fig.1 Enhancing CAR-T cell efficacy through combination modalities.1
Creative Biolabs' Solid Tumor Targeting CAR-T Combination Development Services encompass three strategic approaches: TRUCK CAR-T for modulating the immunosuppressive TME, Hyaluronidase-armored CAR-T to enhance tumor infiltration, and mRNA vaccine-primed CAR-T to address antigen heterogeneity. These rationally designed solutions collectively enhance safety through precision targeting, improve durability via memory T cell formation, and maximize antitumor efficacy through optimized combination protocols.
Our portfolio of advanced combination strategies focuses on mechanistically counteracting the specific challenges of solid tumors, ensuring the CAR-T cell functions optimally within the hostile environment.
This involves arming CAR-T cells with transgenes that are secreted upon target recognition. This turns the CAR-T cell into a localized TME modifier, directly recruiting and activating endogenous immune cells to break down the tumor's suppressive defenses and reverse T cell exhaustion.
Many solid tumors are protected by a dense extracellular matrix (ECM) rich in hyaluronan, which physically impedes CAR-T cell trafficking. We develop strategies combining CAR-T cells with or engineering them to secrete hyaluronidase. This enzyme breaks down the ECM barrier, dramatically enhancing CAR-T cell infiltration and accumulation at the tumor core.
The mRNA vaccine component primes or boosts the host's endogenous T cell response against a wider range of tumor antigens, while the CAR-T provides the initial, powerful targeted attack. This combination promotes T cell memory and broadens the immune attack, providing superior long-term anti-tumor surveillance.
Required Starting Materials:
Key steps:
Final Deliverables:
What is the primary advantage of combining CAR-T therapy with mRNA vaccines compared to CAR-T therapy alone?
The key advantage of integrating CAR-T therapy with mRNA vaccines lies in the vaccine's ability to drive sustained in vivo expression of tumor antigens, which potently primes and expands CAR-T cells, thereby enhancing the persistence and breadth of antitumor activity while also addressing tumor antigen heterogeneity and reducing the risk of relapse due to antigen escape.
There are concerns regarding the cost and complexity of combination therapies. How does Creative Biolabs validate this strategy?
Our approach is fundamentally designed to enhance therapeutic value and reduce long-term risk. While the initial architecture appears more sophisticated, we streamline development, minimize iterative failures, and provide a more direct and efficient pathway to clinical trials by employing a rationally integrated design.
Capitalizing on twenty years of scientific leadership, Creative Biolabs pioneers a new development paradigm for solid tumor CAR-T therapies. By mastering the complex biology of the TME, we deliver rationally engineered solutions designed to break through the most persistent barriers in the field.
Creative Biolabs is dedicated to advancing your CAR-T development by overcoming the persistent challenges of solid tumor targeting. Leveraging over two decades of specialized experience, we apply deep scientific insight to engineer innovative, collaborative solutions for your most complex therapeutic objectives.
Reach out to our team to explore how we can support your project's success.
Reference
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
